Company profile: XyloCor Therapeutics
1.1 - Company Overview
Company description
- Provider of gene therapies for coronary artery disease: XC001 treats refractory angina by stimulating new coronary blood vessel formation; XC002 is in development to regenerate cardiac tissue in heart failure after past heart attacks by converting non-functioning cardiac cells into functioning ones.
Products and services
- XC002: Cardiac-targeted gene therapy in development to regenerate tissue in heart failure due to past heart attacks by converting non-functioning cardiac cells into functioning myocardium
- XC001: Vascular-targeted gene therapy engineered to treat refractory angina by stimulating the formation of new coronary blood vessels in the heart
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to XyloCor Therapeutics
Rubius Therapeutics
HQ: United States
Website
- Description: Provider of technology to grow, genetically engineer, and mature long-circulating Red-Cell Therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rubius Therapeutics company profile →
BostonGene
HQ: United States
Website
- Description: Provider of AI-powered molecular and immune profiling and a cloud-based platform for personalized cancer therapy analysis; multiplex immunofluorescence (MxIF) pipeline analyzing tissue architecture and cell interactions, detecting up to 40 protein markers; bioinformatics services using multi-omics databases and proprietary software; biopharma solutions and target analysis to evaluate drug candidates in a certified environment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BostonGene company profile →
Axxam
HQ: Italy
Website
- Description: Provider of integrated drug discovery services from target validation to lead generation, including assay development, high-throughput screening and hit-to-lead profiling, with a focus on small-molecule drugs targeting inflammation. Offers RNA biology platforms, SARS-CoV-2 cell-based and biochemical assays, a 349k-compound AXXDiversity library, and the AXXSense platform for flavors, fragrances and taste modulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axxam company profile →
Twist Bioscience
HQ: United States
Website
- Description: Provider of synthetic DNA solutions using a semiconductor-based platform for high-throughput, cost-effective manufacturing; customizable gene synthesis; variant libraries; NGS target enrichment panels for viral genome detection and characterization; synthetic RNA controls for diagnostic quality assurance; antibody development against SARS-CoV-2; and comprehensive viral research panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Twist Bioscience company profile →
Seer
HQ: United States
Website
- Description: Provider of proteomics tools and solutions, including the Proteograph Product Suite (integrated workflow with instruments, consumables, and software for deep, large-scale proteome analysis); Proteograph Analysis Suite for LC-MS data processing, analysis, and visualization; SP100 Automation Instrument; Proteograph Assay Kit; and Seer Technology Access Center services for proteomics research support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seer company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for XyloCor Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to XyloCor Therapeutics
2.2 - Growth funds investing in similar companies to XyloCor Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for XyloCor Therapeutics
4.2 - Public trading comparable groups for XyloCor Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →